Browsing Tag
VK2809
2 posts
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.
Viking Therapeutics initiates VOYAGE study for VK2809 in NASH
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor…